These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7368173)

  • 1. Results of low-dose heparin prophylaxis of venous thrombosis considering plasma heparin and anti-thrombin III concentration.
    Tilsner V; Müller U; Reuter H; Raedler A
    Thromb Res; 1980 Feb 1-15; 17(3-4):519-25. PubMed ID: 7368173
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
    Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
    Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III.
    Bounameaux H; Marbet GA; Lämmle B; Eichlisberger R; Duckert F
    Am J Clin Pathol; 1980 Jul; 74(1):68-73. PubMed ID: 7395817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of the thrombin clotting time and activated partial thromboplastin time to low level of antithrombin III during heparin therapy.
    Delorme MA; Inwood MJ; O'Keefe B
    Clin Lab Haematol; 1990; 12(4):433-6. PubMed ID: 2081384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The determination of heparin].
    Aiach M
    Ann Biol Clin (Paris); 1982; 40(6):645-50. PubMed ID: 7165134
    [No Abstract]   [Full Text] [Related]  

  • 6. Improving use of heparin in acute deep venous thrombosis.
    Gold JA; Ferguson CJ; Williams NF; Braun SK
    Wis Med J; 1996 May; 95(5):311-2. PubMed ID: 8936037
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapy of deep venous thrombosis].
    Mesters RM
    Internist (Berl); 1999 Oct; 40(10):1098-9. PubMed ID: 10610366
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma heparin values and hemostasis in equids after subcutaneous administration of low-dose calcium heparin.
    Gerhards H; Eberhardt C
    Am J Vet Res; 1988 Jan; 49(1):13-8. PubMed ID: 3354959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative efficacy of heparin and related glycosaminoglycans as antithrombotic drugs.
    Thomas DP; Merton RE; Barrowcliffe TW
    Ann N Y Acad Sci; 1989; 556():313-22. PubMed ID: 2735662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-antithrombin III binding. In vitro and in vivo studies.
    Chan V; Chan TK
    Haemostasis; 1979; 8(6):373-89. PubMed ID: 511016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study on the effects of a low molecular weight heparin (CY 216) and standard heparin in low dosage on experimental venous thrombosis.
    Doutremepuich C; Bousquet F; Gestreau GL; Toulemonde F; Bayrou B
    Haemostasis; 1987; 17(4):201-5. PubMed ID: 3623263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Perioperative plasma antithrombin activity with "low-dose" heparin prophylaxis. Perioperatively acquired antithrombin III deficiency as a cause for the failure of heparin prophylaxis?].
    Kussmann J; Hirche H; Sengupta R
    Dtsch Med Wochenschr; 1983 Mar; 108(12):449-52. PubMed ID: 6832015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro and ex-vivo neutralizing effect of protamine sulphate on the anticoagulant activity of a new low molecular mass heparin.
    Falkon L; Garí M; Gich I; Fontcuberta J
    Thromb Res; 1998 Jan; 89(2):79-83. PubMed ID: 9630311
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevention of venous thrombosis after total hip arthroplasty. Antithrombin III and low-dose heparin compared with dextran 40.
    Francis CW; Pellegrini VD; Marder VJ; Harris CM; Totterman S; Gabriel KR; Baughman DJ; Roemer S; Burke J; Goodman TL
    J Bone Joint Surg Am; 1989 Mar; 71(3):327-35. PubMed ID: 2466846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
    Schumacher WA; Steinbacher TE; Heran CL; Seiler SM; Michel IM; Ogletree ML
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1237-42. PubMed ID: 8263785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antithrombin III in 86 patients with venous thrombosis (author's transl)].
    Juillet Y; Aiach M; Fiessinger JN; Leclerc M; Housset E
    Sem Hop; 1978 Nov 8-15; 54(37-40):1126-9. PubMed ID: 217091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thrombin-antithrombin III complexes as a measure of effective heparin treatment?].
    Meyer D; Tsakiris DA; Marbet GA
    Schweiz Med Wochenschr; 1989 Sep; 119(39):1352-4. PubMed ID: 2678451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of antithrombin III and effect of heparin on coagulation in shock.
    Blauhut B; Necek S; Kramar H; Vinazzer H; Bergmann H
    Thromb Res; 1980 Sep; 19(6):775-82. PubMed ID: 7466746
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.